SignaBlok Achieves Key in Vivo Proof of Concept for Treatment of Cancer and Sepsis
Novel First-in-Class Peptide Inhibitor of TREM-1 Modulates the Inflammatory Response and Shows Promise for Treatment of Cancer and Sepsis - September 18, 2013
SignaBlok Awarded NCI Grant to Test New Approach to Lung Cancer Treatment
SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Cancer Institute (NCI) to develop novel and first-in-class agents in lung cancer. - October 03, 2012
SignaBlok Awarded NIH Grant to Develop New Nanotechnology for Diagnostic Imaging of Atherosclerosis
SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Institutes of Health (NIH) to develop multifunctional nanoformulations for diagnostic imaging of atherosclerosis. - July 12, 2012
SignaBlok Awarded DARPA Contract to Support New Technology to Combat Sepsis
SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to introduce company’s new approach to the prevention and treatment of sepsis (blood poisoning). - January 12, 2012